Ascidian and Roche to develop RNA therapies for neurological diseases

19 Jun 2024
·
Deals
www.pharmaceutical-technology.com
VaccineLicense out/inDrug ApprovalmRNAAcquisition
Ascidian and Roche to develop RNA therapies for neurological diseases
Preview
Source: Pharmaceutical Technology
Ascidian retains the freedom to pursue other neurological targets independently or with different collaborators. Credit: Komsan Loonprom / Shutterstock.
Ascidian and Roche to develop RNA therapies for neurological diseases
Preview
Source: Pharmaceutical Technology
Ascidian Therapeutics has entered a research partnership and licensing agreement with Roche to discover and develop RNA exon editing therapies to treat neurological diseases.
The partnership will leverage Ascidian’s RNA exon editing platform to extend the therapeutic potential of the medicine beyond the capabilities of current gene editing technologies.
Ascidian will grant Roche sole rights to utilise its RNA exon editing technology for undisclosed neurological targets.
Ascidian will conduct discovery and some preclinical works together with Roche.
Roche will assume responsibility for additional preclinical activities, alongside clinical development, production and commercialisation of the assets.
See Also:FDA grants approval for Alexion’s NMOSD treatment
Ascidian and Roche to develop RNA therapies for neurological diseases
Preview
Source: Pharmaceutical Technology
AbbVie signs agreement to acquire Landos Biopharma for $212.5m
Ascidian and Roche to develop RNA therapies for neurological diseases
Preview
Source: Pharmaceutical Technology
Ascidian is entitled to receive an upfront payment of $42m from Roche, and could receive up to $1.8bn in milestone payments on meeting research, clinical and commercial goals.
Ascidian will earn royalty payments on global commercial product sales from Roche.
Despite this exclusive arrangement for specific targets, Ascidian can pursue other neurological targets independently or with different collaborators.
The platform developed by Ascidian is capable of editing RNA exons on a kilobase scale, enabling it to target large genes and those with a high degree of mutational variance.
The technology preserves natural gene expression patterns and levels.
Ascidian Therapeutics president and CEO Michael Ehlers said: “Roche is known and respected worldwide for their expertise in complex neurological diseases. I am proud of the scientific rigour and quality of the work done at Ascidian that has led to this partnership.
“The potential of treating disease by large-scale exon editing of RNA is vast. We look forward to working with the Roche team to develop first-in-class RNA exon editing medicines for multiple neurological diseases, with a mission and passion to relieve suffering and improve lives.”
The European Commission recently approved Roche’s Alecensa (alectinib) as the first adjuvant treatment for adults with anaplastic lymphoma kinase positive non-small cell lung canceranaplastic lymphoma kinase positive non-small cell lung cancer post-tumour resection with high recurrence risk.
mRNA vaccine coverage on Pharmaceutical Technology (Or Clinical Trials Arena)  is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepapermRNA capping: low cost, high reward
Are you aware of the latest mRNA capping techniques? The success of mRNA-based Covid vaccines has seen the technology boom in popularity – but capping is an essential part of the manufacturing process, and pharmaceutical firms face a range of choices on how to do it. This free whitepaper assesses differences in price, time, complexity and availability for the methods on offer – and provides essential insights on TriLink’s trailblazing CleanCap® approach. Fill in your details to find out more.
Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
By Trilink Thematic
Ascidian and Roche to develop RNA therapies for neurological diseases
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Trilink Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.